HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Biomarker Assessment and Related Treatment Decision-Making

Featuring an interview with Dr Seth Wander, including the following topics:

• Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00)
• Potential role of thymidine kinase testing in monitoring response to therapy (4:56)
• Interpretation of next-generation sequencing testing; use of targeted therapy (10:59)
• Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19)
• Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07)
• Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15)
• Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26)
• Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10)
• Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31)
• Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36)
• Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59)

CME information and select publications